KR20040052442A - 신규한 섬유아세포 성장 인자 - Google Patents

신규한 섬유아세포 성장 인자 Download PDF

Info

Publication number
KR20040052442A
KR20040052442A KR10-2003-7007614A KR20037007614A KR20040052442A KR 20040052442 A KR20040052442 A KR 20040052442A KR 20037007614 A KR20037007614 A KR 20037007614A KR 20040052442 A KR20040052442 A KR 20040052442A
Authority
KR
South Korea
Prior art keywords
fgf
polypeptide
nucleotide sequence
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2003-7007614A
Other languages
English (en)
Korean (ko)
Inventor
페터 베. 브링만
데릴 폴즈
브라니슬라바 미트로빅
수바 스리니바산
제임스 오누퍼
Original Assignee
쉐링 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쉐링 악티엔게젤샤프트 filed Critical 쉐링 악티엔게젤샤프트
Publication of KR20040052442A publication Critical patent/KR20040052442A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR10-2003-7007614A 2000-12-08 2001-12-10 신규한 섬유아세포 성장 인자 Ceased KR20040052442A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25183700P 2000-12-08 2000-12-08
US60/251,837 2000-12-08
US10/005,646 2001-12-07
US10/005,646 US20020151496A1 (en) 2000-12-08 2001-12-07 Novel fibroblast growth factors
PCT/US2001/047350 WO2002046424A2 (en) 2000-12-08 2001-12-10 Fibroblast growth factors

Publications (1)

Publication Number Publication Date
KR20040052442A true KR20040052442A (ko) 2004-06-23

Family

ID=26674594

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-7007614A Ceased KR20040052442A (ko) 2000-12-08 2001-12-10 신규한 섬유아세포 성장 인자

Country Status (21)

Country Link
US (2) US20020151496A1 (https=)
EP (1) EP1389237A2 (https=)
JP (1) JP2005506275A (https=)
KR (1) KR20040052442A (https=)
CN (1) CN1518597A (https=)
AU (1) AU2603402A (https=)
BG (1) BG107888A (https=)
BR (1) BR0116507A (https=)
CA (1) CA2431374A1 (https=)
CZ (1) CZ20031570A3 (https=)
EE (1) EE200300269A (https=)
HU (1) HUP0400657A1 (https=)
IL (1) IL156259A0 (https=)
MX (1) MXPA03005142A (https=)
NO (1) NO20032573L (https=)
PL (1) PL366158A1 (https=)
RU (1) RU2329058C2 (https=)
SI (1) SI21372A (https=)
SK (1) SK7012003A3 (https=)
WO (1) WO2002046424A2 (https=)
ZA (1) ZA200305236B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253266B2 (en) 1999-07-27 2007-08-07 Curagen Corporation Polypeptides of FGF-CX
US6982250B2 (en) 2000-11-06 2006-01-03 Curagen Corporation Methods of prevention and treatment of inflammatory bowel disease
US7189693B2 (en) 2000-11-06 2007-03-13 Curagen Corporation Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides
JP2005519891A (ja) * 2002-01-15 2005-07-07 イーライ・リリー・アンド・カンパニー 危篤状態の患者における罹病率および死亡率を低下させる方法
ATE482725T1 (de) 2003-04-01 2010-10-15 Us Dept Of Veteran S Affaires Auf stammzellen, vorläuferzellen oder targetzellen basierende behandlung von multiorganversagen.
WO2004105787A1 (en) * 2003-05-28 2004-12-09 The University Of Kyoto Methods of using combinations of egf-2 and egf-20 to treat central nervous system disorders
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
HK1214832A1 (zh) 2012-11-28 2016-08-05 恩格姆生物制药公司 用於代謝病症和疾病治療的組合物和方法
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2015065897A1 (en) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
PT3097122T (pt) 2014-01-24 2020-07-21 Ngm Biopharmaceuticals Inc Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN114129709A (zh) 2014-10-23 2022-03-04 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
CN107050428B (zh) * 2017-03-23 2020-05-05 温州医科大学 Fgf20药物及其对脑创伤的治疗应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
AU3924300A (en) * 1999-04-02 2000-10-23 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
WO2001031008A2 (en) * 1999-10-22 2001-05-03 Chiron Corporation Human and rat fgf-20 genes and gene expression products
WO2001036640A2 (en) * 1999-11-18 2001-05-25 Chiron Corporation Human fgf-21 gene and gene expression products
WO2001092522A2 (en) * 2000-06-01 2001-12-06 Eli Lilly And Company Human fgf-20 nucleic acids and polypeptides
WO2002002625A2 (en) * 2000-07-03 2002-01-10 Curagen Corporation Novel fibroblast growth factors and nucleic acids encoding same

Also Published As

Publication number Publication date
CA2431374A1 (en) 2002-06-13
MXPA03005142A (es) 2004-10-15
WO2002046424A3 (en) 2003-11-27
EP1389237A2 (en) 2004-02-18
NO20032573D0 (no) 2003-06-06
US20020151496A1 (en) 2002-10-17
BG107888A (bg) 2004-08-31
IL156259A0 (en) 2004-01-04
CZ20031570A3 (cs) 2004-01-14
PL366158A1 (en) 2005-01-24
NO20032573L (no) 2003-07-22
AU2603402A (en) 2002-06-18
SK7012003A3 (en) 2004-04-06
CN1518597A (zh) 2004-08-04
ZA200305236B (en) 2005-06-29
HUP0400657A1 (en) 2006-04-28
SI21372A (sl) 2004-06-30
BR0116507A (pt) 2004-01-06
EE200300269A (et) 2003-10-15
WO2002046424A2 (en) 2002-06-13
RU2329058C2 (ru) 2008-07-20
AU2002226034A2 (en) 2002-06-18
JP2005506275A (ja) 2005-03-03
US20080057076A1 (en) 2008-03-06
RU2003119657A (ru) 2005-02-27

Similar Documents

Publication Publication Date Title
US20080057076A1 (en) Novel fibroblast growth factors
KR100924183B1 (ko) 신규 섬유아세포 성장 인자 (ｆｇｆ23) 및 그의 이용 방법
AU769166B2 (en) Fizz proteins
HUE035043T2 (en) A pharmaceutical composition for promoting functional regeneration of damaged tissue
KR20020003353A (ko) Ｎｏｇｏ 유전자의 뉴클레오티드와 단백질 서열 및 이들에기초한 방법
JPH09510103A (ja) 線維芽細胞成長因子−１０
WO1998022499A2 (en) Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof
WO1998022499A9 (en) Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof
JP2002525086A (ja) 血小板由来増殖因子ｃ、それをコードするｄｎａ、及びその利用法
WO1998007736A9 (en) Don-1 gene and polypeptides and uses therefor
EP1015474A1 (en) Don-1 gene and polypeptides and uses therefor
AU2002226034B2 (en) Fibroblast growth factors
JP2004504042A (ja) グリコシル化ｖｅｇｆ−ｂ及び可溶性ｖｅｇｆ−ｂの量を増加させるための方法
AU2007203341A1 (en) Fibroblast growth factors
AU2002226034A1 (en) Fibroblast growth factors
US6677117B1 (en) Human polyhomeotic 2 (hph2) acts as a tumor suppressor
WO1998017798A1 (en) Placental-derived prostate growth factors
HK1068648A (en) Novel fibroblast growth factors
US20020127594A1 (en) Don-1 gene and polypeptides and uses therefor
EP1208198A2 (en) Egfh2 genes and gene products
US6537554B1 (en) Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
CA2335326A1 (en) Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US20030104573A1 (en) Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20030605

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20061211

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20071106

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20080702

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20071106

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I